Journal article

Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial.

S van Dieren, AP Kengne, J Chalmers, JWJ Beulens, TME Davis, G Fulcher, SR Heller, A Patel, S Colagiuri, P Hamet, G Mancia, M Marre, B Neal, B Williams, LM Peelen, YT van der Schouw, M Woodward, S Zoungas

Diabetes Obes Metab | Published : 2014

Abstract

AIMS: The aim of this study was to assess associations between patient characteristics, intensification of blood glucose-lowering treatment through oral glucose-lowering therapy and/or insulin and effective glycaemic control in type 2 diabetes. METHODS: 11 140 patients from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) trial who were randomized to intensive glucose control or standard glucose control and followed up for a median of 5 years were categorized into two groups: effective glycaemic control [haemoglobin A1c (HbA1c) ≤ 7.0% or a proportionate reduction in HbA1c over 10%] or ineffective glycaemic control (HbA1c > 7.0% and a prop..

View full abstract

University of Melbourne Researchers